IP Library Granted Patent US 8,715,699
Granted Patent B2
US 8,715,699 · App. 13/518,981 · Granted May 6, 2014

Amino acid conjugates of quetiapine, process for making and using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,699
App. No.
13/518,981
Granted
May 6, 2014
Kind
B2
Abstract

The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.

Claims (13)

1. A composition for treating a psychiatric disorder in a subject comprising 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine), conjugated to phenylalanine via an ester bond.

2. The composition of claim 1 , wherein the composition has a higher relative bioavailability than non-conjugated quetiapine when administered orally.

3. The composition of claim 1 , wherein the composition is formulated for oral or suppository administration.

4. The composition of claim 3 , wherein the composition formulated for oral administration is a tablet, capsule, caplet, pill, troche, lozenge, liquid solution, suspension, elixir or oral thin film.

5. The composition of claim 1 , wherein the conjugate is present in an amount of between about 1 mg and 2000 mg per unit dose.

6. The composition of claim 4 , wherein the conjugate is present in an amount of between about 150 and 800 mg per unit dose.

7. The composition of any one of claim 5 or 6 , wherein the presence of quetiapine is based on molar equivalent of unconjugated quetiapine.

8. The composition of claim 1 , further comprising one or more of: lithium, divalproex, antiadherents, binders, coatings, disintegrants, fillers, flavors and colors, glidants, lubricants, preservatives, sorbents and sweeteners.

9. The composition of any one of claim 1 or 5 , wherein the composition comprises a salt of the conjugate.

10. The composition of claim 9 , wherein the salt is a hydrochloride salt, a hydrobromide salt, a hydroiodide salt, a sulfate, a phosphate, an organic acid salt, a nitrate, a benzoate or a mixture thereof.

11. A composition for treating a psychiatric disorder in a subject comprising quetiapine, conjugated to phenylalanine via an ester bond wherein the conjugate is represented by any one of the following structures of formulas V-VI:

12. A method of treating a psychiatric disorder comprising a step of administering to a subject a composition comprising a therapeutically effective amount of 2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethanol (quetiapine), conjugated to phenylalanine via an ester bond, or a pharmaceutically acceptable salt thereof.

13. The composition of claim 10 , wherein the organic acid salt is a mesylate salt, a besylate salt, a tosylate salt, an oxalate salt, a fumarate salt, a triflate salt, a citrate salt, a malate salt, or a tartarate salt.

Assignments (7)
RELEASE OF SECURITY INTEREST Recorded Mar 13, 2026
From: ALTER DOMUS (US) LLC
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 075080/0907 →
SECURITY INTEREST Recorded Apr 8, 2024
From: ZEVRA THERAPEUTICS, INC.
To: ALTER DOMUS (US) LLC
Reel/Frame 067040/0637 →
CHANGE OF NAME Recorded Feb 23, 2024
From: KEMPHARM, INC.
To: ZEVRA THERAPEUTICS, INC.
Reel/Frame 066664/0108 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2021
From: DEERFIELD PRIVATE DESIGN FUND III, L.P.
To: KEMPHARM, INC.
Reel/Frame 056803/0133 →
SECURITY INTEREST Recorded Feb 28, 2020
From: KEMPHARM, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 051968/0714 →
SECURITY INTEREST Recorded Jun 3, 2014
From: KEMPHARM, INC.
To: DEERFIELD PRIVATE DESIGN FUND III, L.P.
Reel/Frame 033079/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2012
From: MICKLE, TRAVIS; GUENTHER, SVEN; BERA, SANJIB
To: KEMPHARM, INC.
Reel/Frame 028615/0489 →